Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Generic Apixaban vs ELIQUIS in Healthy Thai Volunteers
NCT06388239Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Aug 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of apixaban in thromboembolism (2 arms), sponsored by International Bio Service. Primary endpoints: Peak Plasma Concentration, Area Under the Curve (0-36h) and 1 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
apixaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT06388239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06388239.